Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)

Gregory Lip, Naab Al-Saady, James Jin, Ming Sun, Michael Melino, Shannon M. Winters, Dmitry Zamoryakhin, Andreas Goette

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
186 Downloads (Pure)

Abstract

In the ENSURE-AF study (NCT 02072434), edoxaban was compared to enoxaparin–warfarin in 2199 patients undergoing electrical cardioversion of non-valvular atrial fibrillation (AF). In this multicenter PROBE trial, we analyzed patients randomized to enoxaparin–warfarin. We determined time to achieve therapeutic range (TtTR), time in therapeutic range (TiTR), their clinical determinants, relation to SAMe-TT2R2 score, and impact on primary endpoints (composite of stroke, systemic embolic event [SEE], myocardial infarction [MI], and cardiovascular death [CVD] and composite of major + clinically relevant non-major [CRNM] bleeding). Among 1104 patients randomized to enoxaparin––warfarin, 27% were oral anticoagulant naïve. Mean age was 64.2±11 years and mean CHA2DS2-VASc score was 2.6. Mean TtTR was 7.7 days (median 7 days) and mean TiTR after reaching INR 2.0–3.0 was 71%. In 695 patients with INR <2.0 prior to first dose and who reached ≥2.0, 436 had a SAMe-TT2R2 score ≤2 and 259 a score of >2. On multivariate regression, an independent predictor of extended TtTR was creatinine clearance (CrCl) [P=0.02]. TtTR was marginally related to stroke/SEE/MI/CVD (P=0.06; OR=0.23, 95% CI 0.02–1.17) but not to any bleeding. Independent predictors of TiTR were prior VKA experience (P<0.01) and low HAS-BLED score (P=0.02). TiTR was related to any bleeding (P=0.02; OR=0.39, 95% CI 0.16–0.88), but not stroke/SE/MI/CVD. In this cohort of warfarin users with a high TiTR no difference was seen between TtTR and TiTR in relation to SAMe-TT2R2 score. In conclusion, even in this short-term study, TiTR was significantly related to bleeding events.
Original languageEnglish
JournalThe American Journal of Cardiology
Early online date15 Jun 2017
DOIs
Publication statusE-pub ahead of print - 15 Jun 2017

Keywords

  • warfarin
  • time in therapeutic range
  • bleeding
  • stroke

Fingerprint

Dive into the research topics of 'Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)'. Together they form a unique fingerprint.

Cite this